Enzo Biochem, Inc. (NYSE:ENZ)

CAPS Rating: 1 out of 5

The Company is a life sciences and biotechnology company focused on harnessing genetic processes to develop research tools, diagnostics and therapeutics and a provider of diagnostic services to the medical community.

Results 1 - 13 of 13

Recs

0
Member Avatar augustin949 (< 20) Submitted: 6/29/2014 9:24:21 PM : Outperform Start Price: $4.91 ENZ Score: -43.36

The appeal court will award 0ver 80mill August/September. The book value it is a lot higher then market value.

Recs

0
Member Avatar michaeltbryant (< 20) Submitted: 9/19/2009 8:47:21 AM : Outperform Start Price: $7.05 ENZ Score: -147.45

Up on huge volume.

Recs

0
Member Avatar Boum (< 20) Submitted: 8/22/2009 10:23:07 AM : Outperform Start Price: $4.63 ENZ Score: -141.55

What do you think, is this company good manged ?
When I read other pitch it seem not. But I think earning money is not the goal.
They are building knowledge for future...
The stock is cheap, potential high and when other pharmaceutic company will have cash again...

Recs

1
Member Avatar trm3 (< 20) Submitted: 9/10/2008 2:54:17 PM : Outperform Start Price: $11.23 ENZ Score: -139.92

pwr 10

Recs

0
Member Avatar MC40 (53.08) Submitted: 8/23/2008 9:09:10 PM : Outperform Start Price: $13.64 ENZ Score: -138.52

They're makin' money.

Recs

0
Member Avatar marv818 (< 20) Submitted: 12/24/2007 10:32:01 PM : Outperform Start Price: $14.40 ENZ Score: -119.75

The company will be sold within several months

Recs

0
Member Avatar MM4L (84.67) Submitted: 9/7/2007 6:22:37 PM : Outperform Start Price: $12.70 ENZ Score: -120.54

Okay, Enzo took their hit and lost $5 in one day. At $12.56, they are a good value stock in a good bio-tech player, looking to rebound. If they win the litigation, they will pop up over $18.. maybe $20.

Let's get real. They have over 200 patents and 180 more pending. This is THEM suing others for infringment.. it is not like THEY were the ones infringing. I find it hard to believe 25-30% of their value was solely based upon this suit and it's outcome.

I think if you were a previous "inderperform" voter, now would be a good time to see that this stock has corrected and is due to head upward from here, at tleast doe the next 1-2 years.

I see this stock hitting $15-16 in the next 3-6 months. You can wait and watch or pan the stock and miss out on the upward movement.

I'm in for 500 shares at $12.58.

Recs

0
Member Avatar Greenrunner (43.65) Submitted: 9/7/2007 11:29:27 AM : Outperform Start Price: $12.65 ENZ Score: -121.33

Oversold

Recs

0
Member Avatar SanDieguito (< 20) Submitted: 9/7/2007 11:06:52 AM : Underperform Start Price: $12.87 ENZ Score: +121.56

US District Court ruled against this bio-chemical company in a patent infringement case brought by this company. The six disputed patents relate to the company's method and materials for detecting nucleic acid sequences. Lost $5

Recs

0
Member Avatar davidhs61257 (< 20) Submitted: 8/23/2007 9:51:44 PM : Outperform Start Price: $16.05 ENZ Score: -125.30

Will win patent ligigation with Applera

Recs

0
Member Avatar mgpartners (< 20) Submitted: 7/19/2007 2:46:48 PM : Outperform Start Price: $14.14 ENZ Score: -115.00

ENZO OWNS OVER 200 BIO TECH PATENTS. MANY
PRODUCTS IN SECOND STAGE. A HORDE OF CASH .CHECK THEIR WEBSITE. TALK TO LARZARD WHO DID A SUBSTANTIAL PLACEMENT LAST YEAR. THE SHOT INTEREST AS OF 12 JUN- 18.3% , INSTITUTIONS HOLD 41%. YOU CAN ALSO CALL ED LEWIS AT CEOcast 212-732-4300

Recs

0
Member Avatar jeffreykoo (< 20) Submitted: 5/4/2007 11:41:19 AM : Outperform Start Price: $16.98 ENZ Score: -122.74

stock price moved upwards in spite of negative consensus. In stock market peple who vote with their money (buying power)ften overweight people vote with their heart. A company no one loves usually does better in the long run.

Recs

0
Member Avatar Baldpate12ga (22.02) Submitted: 12/18/2006 9:58:48 PM : Outperform Start Price: $13.95 ENZ Score: -128.96

12/18/06 from Red Herring-- Life sciences firm Enzo Biochem, which launched a patent war by claiming that it invented a technique central to DNA sequencing, has raised $43.1 million by selling stock to institutional investors.

Results 1 - 13 of 13

Featured Broker Partners


Advertisement